GlassScriptPhysician profile
Matthew J Gray
NPI 1396001038
$10,713.15
in general payments reported to CMS, 2019-2025
27 companies · $3,945 in 2025
The $3,945 reported for 2025 was more than what 92% of Pain Medicine (Physical Medicine & Rehabilitation) providers received nationally (typical 2025 total: $400).
See the full distribution for Pain Medicine (Physical Medicine & Rehabilitation)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $384 · 2020: $174 · 2021: $990 · 2022: $2,606 · 2023: $1,380 · 2024: $1,234 · 2025: $3,945.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,848 · Travel and Lodging: $1,710.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,848.22 |
| Travel and Lodging | $1,710.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $2,119.31 | 2021-2025 | Proclaim, Eterna, Prodigy |
| Nevro Corp. | $2,020.53 | 2021-2024 | Senza |
| Medtronic, INC. | $1,356.65 | 2021-2025 | Inceptiv |
| Boston Scientific Corporation | $1,243.28 | 2019-2025 | Intracept, Wavewriter Alpha Prime 16, Na |
| Mml US, INC. | $770.21 | 2025 | Reactiv8 |
| Abbvie INC. | $416.06 | 2022-2025 | |
| Saluda Medical Americas, INC. | $390.11 | 2024-2025 | Evoke |
| Allergan, INC. | $382.52 | 2020-2022 | |
| Bausch & Lomb Americas INC. | $349.85 | 2022-2025 | Envista Mx60 Iol, Vyzulta, Miebo |
| Spr Therapeutics, INC | $292.72 | 2023-2024 | Sprint Pns System |
| Globus Medical, INC. | $288.84 | 2025 | Senza, Vyrsa V1 |
| Nalu Medical, INC. | $149.03 | 2025 | Nalu Neurostimulation System |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $128.05 | 2021-2025 | Relistor |
| Stryker Corporation | $122.46 | 2025 | Optablate |
| Collegium Pharmaceutical, INC. | $101.59 | 2022-2023 | Belbuca |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Relievant Medsystems, INC. | $96.43 | 2023 | Intracept |
| Pfizer INC. | $92.78 | 2021-2024 | |
| Scilex Pharmaceuticals INC. | $86.43 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $78.92 | 2021 | |
| Medtronic USA, INC. | $67.15 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $45.82 | 2022 | |
| Sun Pharmaceutical Industries INC. | $30.94 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $20.55 | 2025 | Dysport |
| Dompe US, INC. | $18.28 | 2022 | |
| Ibsa Pharma INC. | $16.40 | 2023 | Tirosint, Licart |
| Oyster Point Pharma, INC. | $14.27 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $13.97 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Gray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.